$585 Million is the total value of Casdin Capital, LLC's 31 reported holdings in Q4 2018. The portfolio turnover from Q3 2018 to Q4 2018 was 0.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| LOXO | LOXO ONCOLOGY INC | $50,425,000 | -18.0% | 360,000 | 0.0% | 8.63% | +15.4% | |
| CDXS | CODEXIS INC | $33,818,000 | -2.6% | 2,025,000 | 0.0% | 5.79% | +37.1% | |
| FATE | FATE THERAPEUTICS INC | $32,717,000 | -21.2% | 2,550,000 | 0.0% | 5.60% | +10.9% | |
| SAGE | SAGE THERAPEUTICS INC | $29,886,000 | -32.2% | 312,000 | 0.0% | 5.11% | -4.5% | |
| BLFS | BIOLIFE SOLUTIONS INC | $29,216,000 | -31.3% | 2,428,571 | 0.0% | 5.00% | -3.3% | |
| NVTA | INVITAE CORP | $26,544,000 | -33.9% | 2,400,000 | 0.0% | 4.54% | -6.9% | |
| GRTS | GRITSTONE ONCOLOGY INC | $11,133,000 | +8.5% | 720,586 | 0.0% | 1.90% | +52.8% | |
| EVH | EVOLENT HEALTH INCcl a | $10,973,000 | -29.8% | 550,000 | 0.0% | 1.88% | -1.1% | |
| BGNE | BEIGENE LTDsponsored adr | $9,818,000 | -18.6% | 70,000 | 0.0% | 1.68% | +14.7% | |
| FIXX | HOMOLOGY MEDICINES INC | $7,826,000 | -2.2% | 350,000 | 0.0% | 1.34% | +37.8% | |
| CDNA | CAREDX INC | $5,028,000 | -12.9% | 200,000 | 0.0% | 0.86% | +22.7% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2019-02-13
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| BLUEPRINT MEDICINES CORP | 32 | Q3 2023 | 9.6% |
| ALNYLAM PHARMACEUTICALS INC | 32 | Q3 2023 | 9.9% |
| AGIOS PHARMACEUTICALS INC | 27 | Q2 2022 | 12.1% |
| GLOBAL BLOOD THERAPEUTICS IN | 27 | Q2 2022 | 7.1% |
| FATE THERAPEUTICS INC | 26 | Q3 2023 | 8.3% |
| BIOLIFE SOLUTIONS INC | 22 | Q3 2023 | 14.9% |
| CODEXIS INC | 22 | Q3 2023 | 8.1% |
| SAREPTA THERAPEUTICS INC | 21 | Q3 2023 | 13.6% |
| BLUEBIRD BIO INC | 21 | Q4 2020 | 7.8% |
| ILLUMINA INC | 21 | Q3 2023 | 6.0% |
View Casdin Capital, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Absci Corp | May 08, 2023 | 4,448,260 | 4.8% |
| CODEXIS, INC.Sold out | February 14, 2023 | 0 | 0.0% |
| DermTech, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| Invitae Corp | February 14, 2023 | 9,038,388 | 3.7% |
| Magenta Therapeutics, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| Tango Therapeutics, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| Verve Therapeutics, Inc. | February 14, 2023 | 2,290,571 | 3.7% |
| Tenaya Therapeutics, Inc. | December 07, 2022 | 6,427,200 | 9.9% |
| Fulcrum Therapeutics, Inc. | February 11, 2021 | 1,241,176 | 4.5% |
| Gritstone Oncology, Inc.Sold out | February 11, 2021 | 0 | 0.0% |
View Casdin Capital, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2024-05-02 |
| SC 13G | 2024-04-18 |
| SC 13D/A | 2024-04-08 |
| 4 | 2024-03-28 |
| 3 | 2024-03-25 |
| 4 | 2024-03-25 |
| 4 | 2024-03-20 |
| SC 13D/A | 2024-03-20 |
| 4 | 2024-03-06 |
| 4 | 2024-03-06 |
View Casdin Capital, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.